Development of hepatitis C virus vaccines: Challenges and progress

Expert Review of Vaccines

Volumn 8, Issue 3, 2009, Pages 333-345

  Stoll Keller, Françoise ^a   Barth, Heidi ^b   Fafi Kremer, Samira ^a   Zeisel, Mirjam B ^c   Baumert, Thomas F ^c  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c INSERM   (France)

Author keywords

Antibody; Chimpanzee model; HCV; Prophylactic vaccine; Therapeutic vaccine

Indexed keywords

ADENOVIRUS VECTOR; HEPATITIS C VACCINE; NEUTRALIZING ANTIBODY; PEPTIDE VACCINE; PLASMID DNA; VACCINIA VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; HEPATITIS C ANTIBODY; VIRUS VACCINE;

ANTIBODY RESPONSE; B LYMPHOCYTE; CHIMPANZEE; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HEPATITIS C; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS IMMUNITY; ANIMAL; IMMUNOLOGY; MEDICAL RESEARCH; PAN TROGLODYTES;

ANIMALS; BIOMEDICAL RESEARCH; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; PAN TROGLODYTES; T-LYMPHOCYTES, CYTOTOXIC; VIRAL VACCINES;

EID: 63849329322     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.8.3.333     Document Type: Review

References (122)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5(9), 558-567 (2005). (Pubitemid 41196755)
2. Alter MJ. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13(17), 2436-2441 (2007). (Pubitemid 46929498)
3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl. J. Med. 345(1), 41-52 (2001). (Pubitemid 32634271)
4. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436(7053), 961-966 (2005). • Important review on the development of new vaccines. (Pubitemid 41191672)
5. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002).
6. Timm J, Roggendorf M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J. Gastroenterol. 13(36), 4808-4817 (2007). (Pubitemid 47496745)
7. Chevaliez S, Pawlotsky JM. Interferon-based therapy of hepatitis C. Adv. Drug Deliv. Rev. 59(12), 1222-1241 (2007).
8. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132(5), 1979-1998 (2007).
9. Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv. Virus Res. 63, 71-180 (2004). • Describes the molecular biology of hepatitis C virus (HCV). (Pubitemid 39752303)
10. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5(6), 453-463 (2007). • Describes the molecular biology of HCV. (Pubitemid 46780082)
11. Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 282(5386), 103-107 (1998). (Pubitemid 28471138)
12. Drake JW, Charlesworth B, Charlesworth D, Crow JF. Rates of spontaneous mutation. Genetics 148(4), 1667-1686 (1998). (Pubitemid 28180696)
13. Simmonds P. Genetic diversity and evolution of hepatitis C virus - 15 years on. J. Gen. Virol. 85(Pt 11), 3173-3188 (2004). (Pubitemid 39445434)
14. Keck ZY, Machida K, Lai MM, Ball JK, Patel AH, Foung SK. Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. Curr. Top. Microbiol. Immunol. 317, 1-38 (2008).
15. Cocquerel L, Voisset C, Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J. Gen. Virol. 87(Pt 5), 1075-1084 (2006).
16. Tester I, Smyk-Pearson S, Wang P et al. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J. Exp. Med. 201(11), 1725-1731 (2005). (Pubitemid 41002891)
17. + T cell responses during longitudinal study of acute human hepatitis C. Hepatology 42(1), 104-112 (2005). (Pubitemid 40911317)
18. Cox AL, Mosbruger T, Mao Q et al. Cellular immune selection with hepatitis C virus persistence in humans. J Exp. Med. 201(11), 1741-1752 (2005). (Pubitemid 41002893)
19. Uebelhoer L, Han JH, Callendret B et al. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog. 4(9), e1000143 (2008).
20. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285(5424), 110-113 (1999). (Pubitemid 29307577)
21. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197(5), 633-642 (2003). • Describes the development of the pseudotype retrovirus with HCV envelope glycoproteins enabling the study of HCV entry.
22. Hsu M, Zhang J, Flint M et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl Acad. Sci. USA 100(12), 7271-7276 (2003). • Describes the development of the pseudotype retrovirus with HCV envelope glycoproteins enabling the study of HCV entry. (Pubitemid 36706428)
23. Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 44(3), 527-535 (2006). (Pubitemid 44433708)
24. Von HT, Rice CM. Hepatitis C virus entry. J. Biol. Chem. 283(7), 3689-3693 (2008).
25. Evans MJ, Von HT, Tscherne DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446(7137), 801-805 (2007). (Pubitemid 46582027)
26. Haberstroh A, Schnober EK, Zeisel MB et al. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 135(5), 1719-1728 (2008).
27. Pestka JM, Zeisel MB, Blaser E et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl Acad. Sci. USA 104(14), 6025-6030 (2007). (Pubitemid 47175652)
28. Meunier JC, Russell RS, Goossens V et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol. 82(2), 966-973 (2008).
29. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11(7), 791-796 (2005). • Describes the development of a tissue-culture model producing infectious virions. (Pubitemid 41021213)
30. Zhong J, Gastaminza P, Cheng G et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102(26), 9294-9299 (2005). • Describes the development of a tissue-culture model producing infectious virions.
31. Lindenbach BD, Evans MJ, Syder AJ et al. Complete replication of hepatitis C virus in cell culture. Science 309(5734), 623-626 (2005). • Describes the development of a tissue-culture model producing infectious virions.
32. Owsianka AM, Tarr AW, Keck ZY et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol. 89(Pt 3), 653-659 (2008).
33. Zeisel MB, Cosset FL, Baumert TF. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology 48(1), 299-307 (2008).
34. Lavillette D, Morice Y, Germanidis G et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 79(10), 6023-6034 (2005). (Pubitemid 40617208)
35. Von Hahn T, Yoon JC, Alter H et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132(2), 667-678 (2007). • Describes the role of neutralizing antibodies and T-cell response in viral clearance. (Pubitemid 46274668)
36. Fafi-Kremer S, Soulier E, Fofana I et al. Viral entry and escape from antibody-mediated C virus variants during liver transplantation. J. Hepatol. 48(2), 563 (2008) (Abstract).
37. Haberstroh A, Schnober EK, Zeisel MB et al. SEKCPea. Neutralizing host reponses in hepatitis C virus infection target viral entry at post-binding steps and membrane fusion. Gastroenterolgy 135(5), 1719-1728 (2008).
38. Zhang P, Wu CG, Mihalik K et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc. Natl Acad. Sci. USA 104(20), 8449-8454 (2007). (Pubitemid 47175508)
39. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J. Virol. 80(5), 2418-2428 (2006). (Pubitemid 43271547)
40. Bartosch B, Verney G, Dreux M et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 79(13), 8217-8229 (2005). (Pubitemid 40853525)
41. Dreux M, Pietschmann T, Granier C et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J. Biol. Chem. 281(27), 18285-18295 (2006). (Pubitemid 44035485)
42. Dreux M, Cosset FL. The scavenger receptor BI and its Iigand, HDL: partners in crime against HCV neutralizing antibodies. J. Viral Hepat. 14(Suppl. 1), 68-76 (2007). (Pubitemid 47624116)
43. Zeisel MB, Koutsoudakis G, Schnober EK et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 46(6), 1722-1731 (2007).
44. Falkowska E, Kajumo F, Garcia E, Reinus J, Dragic T. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol. 81(15), 8072-8079 (2007). (Pubitemid 47101493)
45. Helle F, Goffard A, Morel V et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 81(15), 8101-8111 (2007). (Pubitemid 47101496)
46. Timpe JM, Stamataki Z, Jennings A et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47(1), 17-24 (2008).
47. Wei X, Decker JM, Wang S et al. Antibody neutralization and escape by HIV-1. Nature 422(6929), 307-312 (2003). (Pubitemid 36378357)
48. Kwong PD, Doyle ML, Casper DJ et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420(6916), 678-682 (2002). (Pubitemid 36764500)
49. Law M, Maruyama T, Lewis J et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14(1), 25-27 (2008).
50. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436(7053), 946-952 (2005). • Imporant review on determinants of viral clearance or persistence. (Pubitemid 41191670)
51. Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med. 191(9), 1499-1512 (2000). (Pubitemid 30257347)
52. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194(10), 1395-1406 (2001). (Pubitemid 33081515)
53. Thimme R, Bukh J, Spangenberg HC et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl Acad. Sci. USA 99(24), 15661-15668 (2002). (Pubitemid 35403988)
54. + T cells in chronic hepatitis C virus infection. J. Immunol. 169(6), 3447-3458 (2002).
55. Weiner AJ, Paliard X, Selby MJ et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J. Virol. 75(15), 7142-7148 (2001). (Pubitemid 32641602)
56. Bassett SE, Guerra B, Brasky K et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33(6), 1479-1487 (2001). (Pubitemid 32496985)
57. Major ME, Mihalik K, Puig M et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J. Virol. 76(13), 6586-6595 (2002). (Pubitemid 34633524)
58. + T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197(12), 1645-1655 (2003). (Pubitemid 36745340)
59. + memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J. Virol. 77(8), 4781-4793 (2003). (Pubitemid 36402828)
60. Grakoui A, Shoukry NH, Woollard DJ et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302(5645), 659-662 (2003).
61. Lanford RE, Guerra B, Chavez D et al. Cross-genotype immunity to hepatitis C virus. J. Virol. 78(3), 1575-1581 (2004). (Pubitemid 38095866)
62. Bukh J, Thimme R, Meunier JC et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J. Virol. 82(16), 8183-8195 (2008).
63. Thimme R, Lohmann V, Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res. 69(3), 129-141 (2006). (Pubitemid 43247333)
64. Urbani S, Amadei B, Fisicaro P et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology 44(1), 126-139 (2006). • Important study on the role of CD8 T-cell responses. (Pubitemid 44049146)
65. Kaplan DE, Sugimoto K, Newton K et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology 132(2), 654-666 (2007). • Important study on the role of CD8 T-cell responses. (Pubitemid 46274664)
66. Chang KM, Rehermann B, McHutchison JG et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Invest. 100(9), 2376-2385 (1997). (Pubitemid 27500163)
67. Weiner A, Erickson AL, Kansopon J et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc. Natl Acad. Sci. USA 92(7), 2755-2759 (1995).
68. Erickson AL, Kimura Y, Igarashi S et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15(6), 883-895 (2001). (Pubitemid 34075370)
69. Timm J, Lauer GM, Kavanagh DG et al. CD8 epitope escape and reversion in acute HCV infection. J. Exp. Med. 200(12), 1593-1604 (2004).
70. Ray SC, Fanning L, Wang XH, Netski DM, Kenny-Walsh E, Thomas DL. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J. Exp. Med. 201(11), 1753-1759 (2005). (Pubitemid 41002894)
71. + T cell response in mediating HCV clearance and evolution. Hepatology 43(3), 563-572 (2006).
72. + lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J. Virol. 76(24), 12423-12434 (2002). (Pubitemid 35386928)
73. + T-cell failure during chronic hepatitis C virus infection. Hepatology 42(4), 828-837 (2005). (Pubitemid 41401120)
74. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 38(6), 1437-1448 (2003). (Pubitemid 37466970)
75. + regulatory T lymphocytes in hepatitis C virus infection. Hepatology 40(5), 1062-1071 (2004). (Pubitemid 39425561)
76. + T cells during chronic hepatitis C virus infection. J. Virol. 79(12), 7860-7867 (2005). (Pubitemid 40756821)
77. + T cells during persistent hepatitis C virus infection. J. Virol. 79(12), 7852-7859 (2005). (Pubitemid 40756820)
78. + T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood 107(11), 4424-4432 (2006). (Pubitemid 43801369)
79. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077), 682-687 (2006). (Pubitemid 43237609)
80. Day CL, Kaufmann DE, Kiepiela P et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443(7109), 350-354 (2006). (Pubitemid 44435155)
81. Urbani S, Amadei B, Tola D et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 80(22), 11398-11403 (2006). (Pubitemid 44706581)
82. Radziewicz H, Ibegbu CC, Fernandez ML et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 81(6), 2545-2553 (2007). (Pubitemid 46447020)
83. Bowen DG, Shoukry NH, Grakoui A et al. Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J. Virol. 82(10), 5109-5114 (2008).
84. Forns X, Bukh J, Purcell RH. The challenge of developing a vaccine against hepatitis C virus. J. Hepatol. 37(5), 684-695 (2002). (Pubitemid 35305553)
85. Lang K, Weiner DB. Immunotherapy for HCV infection: next steps. Expert. Rev. Vaccines 7(7), 915-923 (2008). • Recent review on HCV vaccines.
86. Inchauspe G, Michel ML. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J. Viral Hepat. 14(Suppl. 1), 97-103 (2007). • Recent review on HCV vaccines. (Pubitemid 47624119)
87. Shiina M, Rehermann B. Hepatitis C vaccines: inducing and challenging memory T cells. Hepatology 43(6), 1395-1398 (2006). (Pubitemid 43980119)
88. Steinmann E, Brohm C, Kallis S, Bartenschlager R, Pietschmann T. Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. J. Virol. 82(14), 7034-7046 (2008).
89. Choo QL, Kuo G, Ralston R et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl Acad. Sci. USA 91(4), 1294-1298 (1994). (Pubitemid 24058997)
90. Puig M, Major ME, Mihalik K, Feinstone SM. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22(8), 991-1000 (2004). (Pubitemid 38221092)
91. Forns X, Payette PJ, Ma X et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 32(3), 618-625 (2000).
92. Youn JW, Park SH, Lavillette D et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology 42(6), 1429-1436 (2005). (Pubitemid 43260047)
93. Folgori A, Capone S, Ruggeri L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12(2), 190-197 (2006). (Pubitemid 43214745)
94. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 21(3), 379-384 (2005). (Pubitemid 40246609)
95. Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J. Virol. 72(5), 3827-3836 (1998). (Pubitemid 28188682)
96. Baumert TF, Vergalla J, Satoi J et al. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 117(6), 1397-1407 (1999).
97. Wellnitz S, Klumpp B, Barth H et al. Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J. Virol. 76(3), 1181-1193 (2002). (Pubitemid 34066422)
98. Barth H, Schafer C, Adah MI et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278(42), 41003-41012 (2003). (Pubitemid 37280923)
99. Barth H, Cerino R, Arcuri M et al. Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J. Virol. 79(9), 5774-5785 (2005). (Pubitemid 40548246)
100. Barth H, Ulsenheimer A, Pape GR et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 105(9), 3605-3614 (2005). (Pubitemid 40628207)
101. Barth H, Schnober EK, Neumann-Haefelin C et al. Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J. Virol. 82(7), 3466-3479 (2008).
102. Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 34(2), 417-423 (2001). (Pubitemid 32702356)
103. Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl Acad. Sci. USA 100(11), 6753-6758 (2003). (Pubitemid 36666652)
104. Qiao M, Murata K, Davis AR, Jeong SH, Liang TJ. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology 37(1), 52-59 (2003). (Pubitemid 36042144)
105. Elmowalid GA, Qiao M, Jeong SH et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl Acad. Sci. USA 104(20), 8427-8432 (2007). (Pubitemid 47175504)
106. Rollier CS, Paranhos-Baccala G, Verschoor EJ et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 45(3), 602-613 (2007). (Pubitemid 46450611)
107. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4(10), 762-774 (2004). (Pubitemid 39336293)
108. Youn JW, Hu YW, Tricoche N et al. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J. Virol. 82(21), 10896-10905 (2008). (Pubitemid 352691168)
109. Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect. Dis. 8(6), 379-386 (2008).
110. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J. Hepatol. 48(1), 148-162 (2008). (Pubitemid 350191999)
111. Blackard JT, Sherman KE. HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver? J. Viral Hepat. 15(5), 323-330 (2008).
112. Feray C, Gigou M, Samuel D et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann. Intern. Med. 128(10), 810-816 (1998). (Pubitemid 28267713)
113. Logvinoff C, Major ME, Oldach D et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl Acad. Sci. USA 101(27), 10149-10154 (2004). (Pubitemid 38891210)
114. Meunier JC, Engle RE, Faulk K et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc. Natl Acad. Sci. USA 102(12), 4560-4565 (2005). (Pubitemid 40397151)
115. Davis GL. Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl. 12(9), 1317-1319 (2006). (Pubitemid 44405117)
116. Leroux-Roels G, Depla E, Hulstaert F et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 22(23-24), 3080-3086 (2004). (Pubitemid 39037210)
117. Nevens F, Roskams T, Van VH et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38(5), 1289-1296 (2003). (Pubitemid 37314839)
118. Klade CS, Wedemeyer H, Berg T et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 134(5), 1385-1395 (2008).
119. Firbas C, Jilma B, Tauber E et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 24(20), 4343-4353 (2006).
120. Fournillier A, Gerossier E, Evlache A et al. Therapeutic vaccination against HCV: pre-clinical and clinical evaluation of a novel MVA-based vaccine. Presented at: 15th International Symposium on HCV and Related Viruses, San Antonio, TX, USA, 5-9 October 2008.
121. Yutani S, Yamada A, Yoshida K et al. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 25(42), 7429-7435 (2007). (Pubitemid 47484009)
122. Barth H, Blum HE, Liang TJ, Baumert TF. Novel vaccine strategies. In: State-of-the-Art of Hepatology. Blum HE, Grisham JW, Manns MP (Eds). Kluwer Academic Publishers, Dordrecht, The Netherlands 516-522 (2004).